Skip to search formSkip to main contentSkip to account menu

regorafenib 40 MG Oral Tablet [Stivarga]

Known as: REGORAFENIB MONOHYDRATE 40 mg ORAL TABLET, FILM COATED [Stivarga], Stivarga 40 MG Oral Tablet 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Regorafenib (Stivarga®) is an oral small molecule kinase inhibitor used to treat metastatic colorectal cancer, hepatocellular… 
Review
2018
Review
2018
Regorafenib (Stivarga®) is an oral small-molecule multiple kinase inhibitor. It is indicated worldwide for patients with… 
Review
2018
Review
2018
Regorafenib (Stivarga®), a small molecule inhibitor of multiple kinases, is the first drug to be approved for the treatment of… 
Review
2015
Review
2015
Regorafenib (Stivarga®) is an orally administered small molecule inhibitor of multiple protein kinases, including kinases… 
2015
2015
Regorafenib (Stivarga®) is a new orally available multikinase inhibitor that targets several protein kinases involved in… 
Review
2013
Review
2013
Regorafenib (Stivarga®) is an inhibitor of multiple protein kinases, including those involved in oncogenesis, tumour angiogenesis… 
2013
2013
CHMP-kommitte rekommenderar godkannande av marknadsforingstillstand for Stivarga® (regorafenib) tabletter for behandling av… 
2013
2013
Regorafenib (Stivarga®) is a multi-kinase inhibitor indicated in heavily pretreated patients with mCRC. In the European Union…